Related Experiment Videos
Therapeutic effect on left ventricular hypertrophy by different antihypertensive drugs
1Abteilung Kardiologie, Universität Düsseldorf.
Insights
Left ventricular hypertrophy (LVH) is a major risk for hypertensive heart disease, causing microcirculation issues and heart failure. Long-term antihypertensive therapy should aim to regress LVH and microvascular damage for better outcomes.
Area of Science:
- Cardiology
- Hypertension Research
- Cardiovascular Physiology
Background:
- Left ventricular hypertrophy (LVH) is a significant independent risk factor in hypertensive heart disease.
- LVH initially presents with normal wall stress but leads to diminished coronary reserve due to microcirculatory disturbances.
- Silent ischemic episodes are common in patients with LVH, detectable via Holter monitoring.
Purpose of the Study:
- To investigate the impact of antihypertensive treatment on LVH regression and microvascular function.
- To evaluate the role of different antihypertensive drug classes in managing LVH and associated cardiac complications.
- To explore the potential for improving coronary flow reserve through chronic antihypertensive therapy.
Main Methods:
- Review of clinical data and treatment outcomes for patients with LVH and hypertension.
- Analysis of the effects of calcium antagonists and ACE inhibitors on LVH regression.
- Assessment of preliminary data on the impact of chronic antihypertensive treatment on coronary flow.
Main Results:
- LVH contributes to ventricular dilation and heart failure, modulated by neurohormonal and genetic factors.
- A stepwise treatment approach using calcium antagonists and ACE inhibitors is recommended for LVH management.
- Preliminary findings suggest that chronic antihypertensive treatment may improve coronary flow reserve.
Conclusions:
- Long-term antihypertensive treatment strategies must prioritize the regression of both LVH and microvascular abnormalities.
- Further research is needed to clarify the role of beta-blockers in managing LVH.
- Successful antihypertensive therapy can potentially restore coronary microcirculation and improve cardiac function.
Abstract:
Left ventricular hypertrophy (LVH) constitutes a powerful independent risk factor in hypertensive heart disease. Although initially the wall stress, i.e., left ventricular afterload, remains normal, the coronary reserve is diminished due to disturbances in the microcirculation. This is also shown in the commonly present silent ischemia episodes in Holter monitoring. LVH also causes ventricular dilation and heart failure. Apart from systolic wall stress LVH is modulated by the trophic effects of the sympathetic nervous system and angiotensin II and genetic factors. Long-term antihypertensive treatment must therefore focus on regression of both LVH and the microvascular abnormalities. A step approach for the treatment of the LVH has been recommended on the basis of the experience of this working group with calcium antagonists and ACE inhibitors, whereas the place of beta-blockers is as yet unclear. Preliminary data indicate that coronary flow rescue can also be improved after chronic antihypertensive treatment.